Kaitanni (cadonilimab) / Akesobio 
Welcome,         Profile    Billing    Logout  
 0 Diseases   1 Trial   1 Trial   3 News 


123456789»
  • ||||||||||  Kaitanni (cadonilimab) / Akesobio
    Observational data, Retrospective data, Journal, Metastases:  The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) in advanced non-small (Pubmed Central) -  Nov 13, 2024   
    In this heavily pretreated cohort of advanced NSCLC patients, cadonilimab-based regimens showed moderate antitumor efficacy with a generally tolerable and manageable safety profile. However, more evidence is needed to support the administration of cadonilimab in NSCLC patients refractory to previous anti-PD-1/PD-L1 therapy.
  • ||||||||||  Kaitanni (cadonilimab) / Akesobio
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  AK104-214: AK104 in Neoadjuvant Treatment of Cervical Cancer (clinicaltrials.gov) -  Nov 1, 2024   
    P2,  N=14, Completed, 
    This study protocol and amendments have been approved by the Ethics Committee of West China Hospital (2024(791)). Not yet recruiting --> Completed | N=30 --> 14 | Trial completion date: Jun 2023 --> Sep 2024 | Trial primary completion date: Mar 2023 --> Sep 2024
  • ||||||||||  Kaitanni (cadonilimab) / Akesobio
    Journal:  Cadonilimab is effective and safe in recurrent cervical cancer. (Pubmed Central) -  Oct 26, 2024   
    The data support the use of cadonilimab plus chemotherapy as an efficacious first-line therapy in persistent, recurrent, or metastatic cervical cancer. No abstract available
  • ||||||||||  Kaitanni (cadonilimab) / Akesobio, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date:  CCGLC-011: Combined HAIC, Lenvatinib and Cadonilimab As Conversion Therapy for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) -  Oct 16, 2024   
    P2,  N=36, Recruiting, 
    It underscores that administration of this agent may lead to significant lichenoid lesions and erosions within the oral cavity-an issue warranting increased vigilance from both oncologists and stomatologists. Trial completion date: Jun 2026 --> Jun 2027
  • ||||||||||  CS2009 / CStone Pharma
    CS2009, a novel first-in-class trispecific antibody targeting PD-1, CTLA-4, and VEGFa, demonstrates promising anti-tumor activity in preclinical evaluation (Grand Ballroom AB - George R. Brown Convention Center) -  Oct 4, 2024 - Abstract #SITC2024SITC_1742;    
    To improve the effect of ICB, VEGF inhibitors including bevacizumab, ramucirumab, lenvatinib, etc. were applied to interrupt tumor angiogenesis, hence promote vascular normalization in tumor immune microenvironment, and improve T lymphocyte infiltration...In the studies using immune competent humanized mice, J30 showed superior anti-tumor activities to its major competitors such as cadonilimab, AK112 and volrustomig...Conclusions J30 is a promising trispecific molecule for the treatment of various advanced solid tumors as a next-generation ICB. Current data supports further clinical research on CS2009.
  • ||||||||||  CS2009 / CStone Pharma
    CS2009, a novel first-in-class trispecific antibody targeting PD-1, CTLA-4, and VEGFa, demonstrates promising anti-tumor activity in preclinical evaluation (Exhibit Halls AB - George R. Brown Convention Center) -  Oct 4, 2024 - Abstract #SITC2024SITC_499;    
    To improve the effect of ICB, VEGF inhibitors including bevacizumab, ramucirumab, lenvatinib, etc. were applied to interrupt tumor angiogenesis, hence promote vascular normalization in tumor immune microenvironment, and improve T lymphocyte infiltration...In the studies using immune competent humanized mice, J30 showed superior anti-tumor activities to its major competitors such as cadonilimab, AK112 and volrustomig...Conclusions J30 is a promising trispecific molecule for the treatment of various advanced solid tumors as a next-generation ICB. Current data supports further clinical research on CS2009.
  • ||||||||||  Retrospective data, Journal:  Steven-Johnson Syndrome/Toxic Epidermal Necrolysis is Associated with PD-1/PD-L1 Inhibitors Usage: A Case Series. (Pubmed Central) -  Sep 30, 2024   
    Results We identified 12 SJS/TEN patients who had been treated with PD1/PD-L1 inhibitors: sintilimab had been used in six patients; tislelizumab in two cases; toripalimab, keytruda and cadonilimab each in one case; and an unknown prescription in one case...Conclusion This study unveils a potential, under-recognized cause of SJS/TEN in the cancer patients after analyzing the cases of SJS/TEN in cancer patients with prior exposure to PD-1/PD-L1 inhibitors. This paper also provides clue about the prominent features of SJS/TEN aforesaid, offering insights on the effective management measures for optimizing clinical safety.
  • ||||||||||  Kaitanni (cadonilimab) / Akesobio
    Preclinical imaging evaluation of a bispecific antibody targeting hPD1/CTLA4 using humanized mice (e-Poster Area) -  Sep 27, 2024 - Abstract #EANM2024EANM_1552;    
    After the binding ability of AK104 to PD1/CTLA4 protein was determined, the Kd value of AK104 uptake by PD1/ CTLA4-positive cells was determined with anti-PD1 monoclonal antibody (AK105) and anti-CTLA4 monoclonal antibody as control groups. The results demonstrated the potential of translating 124I-AK104 into a method for screening patients who benefit from immunotherapy and the efficacy, as well as the feasibility, of this method was verified by immuno-PET imaging of humanized mice.
  • ||||||||||  Kaitanni (cadonilimab) / Akesobio
    Trial primary completion date, Metastases:  Study Of Cadonilimab Combined With Radiotherapy In The Treatment of Locally Advanced Cervical Cancer (clinicaltrials.gov) -  Sep 24, 2024   
    P2,  N=33, Recruiting, 
    The results demonstrated the potential of translating 124I-AK104 into a method for screening patients who benefit from immunotherapy and the efficacy, as well as the feasibility, of this method was verified by immuno-PET imaging of humanized mice. Trial primary completion date: Jun 2024 --> Dec 2024
  • ||||||||||  Kaitanni (cadonilimab) / Akesobio, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open:  TALENP001: Neoadjuvant Triple Therapy for Resectable HCC (clinicaltrials.gov) -  Sep 24, 2024   
    P=N/A,  N=20, Recruiting, 
    Trial primary completion date: Jun 2024 --> Dec 2024 Not yet recruiting --> Recruiting